JPM

311.34

+0.76%↑

BAC

53.59

+1.17%↑

WFC

87.18

+1.49%↑

MS

163.99

-0.67%↓

AXP

360.67

+0.56%↑

JPM

311.34

+0.76%↑

BAC

53.59

+1.17%↑

WFC

87.18

+1.49%↑

MS

163.99

-0.67%↓

AXP

360.67

+0.56%↑

JPM

311.34

+0.76%↑

BAC

53.59

+1.17%↑

WFC

87.18

+1.49%↑

MS

163.99

-0.67%↓

AXP

360.67

+0.56%↑

JPM

311.34

+0.76%↑

BAC

53.59

+1.17%↑

WFC

87.18

+1.49%↑

MS

163.99

-0.67%↓

AXP

360.67

+0.56%↑

JPM

311.34

+0.76%↑

BAC

53.59

+1.17%↑

WFC

87.18

+1.49%↑

MS

163.99

-0.67%↓

AXP

360.67

+0.56%↑

Search

Hercules Capital Inc

Gesloten

SectorFinanciën

17.9 2.05

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.87

Max

18.04

Belangrijke statistieken

By Trading Economics

Inkomsten

56M

58M

Verkoop

-22M

80M

K/W

Sectorgemiddelde

11.594

27.54

Dividendrendement

9.08

Winstmarge

72.162

Werknemers

100

EBITDA

45M

102M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+12.78% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

9.08%

3.88%

Volgende dividenddatum

19 nov 2025

Volgende Ex Dividend datum

12 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-88M

3.3B

Vorige openingsprijs

15.85

Vorige sluitingsprijs

17.9

Nieuwssentiment

By Acuity

100%

0%

506 / 529 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Hercules Capital Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 okt 2025, 17:40 UTC

Acquisities, Fusies, Overnames

Orange to Buy Lorca's 50% Stake in MasOrange for $4.9 Billion

31 okt 2025, 23:09 UTC

Winsten

Review & Preview: October Surprise -- Barrons.com

31 okt 2025, 22:44 UTC

Acquisities, Fusies, Overnames

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31 okt 2025, 21:25 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

31 okt 2025, 21:20 UTC

Acquisities, Fusies, Overnames

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

31 okt 2025, 21:12 UTC

Acquisities, Fusies, Overnames

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

31 okt 2025, 21:12 UTC

Acquisities, Fusies, Overnames

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31 okt 2025, 21:12 UTC

Acquisities, Fusies, Overnames

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

31 okt 2025, 20:51 UTC

Acquisities, Fusies, Overnames

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

31 okt 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

31 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

31 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

31 okt 2025, 20:46 UTC

Acquisities, Fusies, Overnames

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

31 okt 2025, 20:22 UTC

Winsten

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

31 okt 2025, 20:02 UTC

Winsten

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

31 okt 2025, 19:55 UTC

Marktinformatie

Crude Futures Fall for Third Straight Month -- Market Talk

31 okt 2025, 19:54 UTC

Acquisities, Fusies, Overnames

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

31 okt 2025, 19:54 UTC

Acquisities, Fusies, Overnames

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

31 okt 2025, 19:26 UTC

Marktinformatie

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

31 okt 2025, 18:30 UTC

Winsten

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

31 okt 2025, 18:23 UTC

Marktinformatie

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

31 okt 2025, 18:09 UTC

Winsten

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31 okt 2025, 18:08 UTC

Winsten

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31 okt 2025, 17:36 UTC

Marktinformatie

Grain Futures Shrug Off Stronger Dollar -- Market Talk

31 okt 2025, 17:31 UTC

Marktinformatie

U.S. Oil Rig Count Falls, Natural Gas Rig Count Rises -- Market Talk

31 okt 2025, 17:16 UTC

Acquisities, Fusies, Overnames

Orange: Acquisition Likely Completed in First Half Next Year

31 okt 2025, 17:15 UTC

Acquisities, Fusies, Overnames

Orange: Agreement Set to Be Signed By Year-Out

31 okt 2025, 17:14 UTC

Acquisities, Fusies, Overnames

Orange: Acquisition Will Strengthen Position in Spain

31 okt 2025, 17:13 UTC

Acquisities, Fusies, Overnames

Orange Will Be Sole Owner of Spain's MasOrange Following Acquisition of Lorca's Stake

31 okt 2025, 17:12 UTC

Acquisities, Fusies, Overnames

Orange Reaches Deal to Buy Lorca's 50% Stake in MasOrange for EUR4.25B

Peer Vergelijking

Prijswijziging

Hercules Capital Inc Prognose

Koersdoel

By TipRanks

12.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20.21 USD  12.78%

Hoogste 24 USD

Laagste 18.5 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Hercules Capital Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Technische score

By Trading Central

17.41 / 17.93Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Hercules Capital Inc

Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, SaaS Finance, energy technology, sustainable
help-icon Live chat